Pathogenetics of the RASopathies

Human Molecular Genetics

Volumn 25, Issue R2, 2016, Pages R123-R132

  Tidyman, William E ^a,c   Rauen, Katherine A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A2ML1 PROTEIN; ACYLTRANSFERASE; ADAPTOR PROTEIN; B RAF KINASE; GUANOSINE TRIPHOSPHATASE; H RAS PROTEIN; K RAS PROTEIN; LZTR1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MYST4 PROTEIN; N RAS PROTEIN; NEUROFIBROMIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; PROTEINASE INHIBITOR; R RAS PROTEIN; RAF PROTEIN; RAF1 PROTEIN; RAS PROTEIN; RASA1 PROTEIN; RASA2 PROTEIN; RIT1 PROTEIN; SOS PROTEIN; SOS2 PROTEIN; SPRED1 PROTEIN; SPROUTY 1 PROTEIN; SPROUTY PROTEIN; SYNAPTIC RAS GTPASE ACTIVATING PROTEIN 1; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL AGING; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SENESCENCE;

EID: 84994153762     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddw191     Document Type: Review

References (61)

1. Rauen, K.A. (2013) The RASopathies. Annu. Rev. Genomics Hum. Genet., 14, 355-369.
2. Yoon, S. and Seger, R. (2006) The extracellular signalregulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors, 24, 21-44.
3. Aoki, Y., Niihori, T., Kawame, H., Kurosawa, K., Ohashi, H., Tanaka, Y., Filocamo, M., Kato, K., Suzuki, Y., Kure, S., et al. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat. Genet., 37, 1038-1040.
4. Estep, A.L., Tidyman, W.E., Teitell, M.A., Cotter, P.D. and Rauen, K.A. (2006) HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am. J. Med. Genet. A, 140, 8-16.
5. Gibbs, J.B., Sigal, I.S., Poe, M. and Scolnick, E.M. (1984) Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc. Natl. Acad. Sci. U. S. A., 81, 5704-5708.
6. McGrath, J.P., Capon, D.J., Goeddel, D.V. and Levinson, A.D. (1984) Comparative biochemical properties of normal and activated human ras p21 protein. Nature, 310, 644-649.
7. Sweet, R.W., Yokoyama, S., Kamata, T., Feramisco, J.R., Rosenberg, M. and Gross, M. (1984) The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature, 311, 273-275.
8. Niihori, T., Aoki, Y., Narumi, Y., Neri, G., Cave, H., Verloes, A., Okamoto, N., Hennekam, R.C., Gillessen-Kaesbach, G., Wieczorek, D., et al. (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat. Genet., 38, 294-296.
9. Schubbert, S., Zenker, M., Rowe, S.L., Boll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.E., et al. (2006) Germline KRAS mutations cause Noonan syndrome. Nat. Genet., 38, 331-336.
10. Schubbert, S., Bollag, G., Lyubynska, N., Nguyen, H., Kratz, C.P., Zenker, M., Niemeyer, C.M., Molven, A. and Shannon, K. (2007) Biochemical and functional characterization of germ line KRAS mutations. Mol. Cell. Biol., 27, 7765-7770.
11. Cirstea, I.C., Kutsche, K., Dvorsky, R., Gremer, L., Carta, C., Horn, D., Roberts, A.E., Lepri, F., Merbitz-Zahradnik, T., Konig, R., et al. (2010) A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat. Genet., 42, 27-29.
12. Flex, E., Jaiswal, M., Pantaleoni, F., Martinelli, S., Strullu, M., Fansa, E.K., Caye, A., De Luca, A., Lepri, F., Dvorsky, R., et al. (2014) Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. Hum. Mol. Genet., 23, 4315-4327.
13. Shi, G.X. and Andres, D.A. (2005) Rit contributes to nerve growth factor-induced neuronal differentiation via activation of B-Raf-extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades. Mol. Cell. Biol., 25, 830-846.
14. Shi, G.X., Cai, W. and Andres, D.A. (2013) Rit subfamily small GTPases: regulators in neuronal differentiation and survival. Cell. Signal., 25, 2060-2068.
15. Aoki, Y., Niihori, T., Banjo, T., Okamoto, N., Mizuno, S., Kurosawa, K., Ogata, T., Takada, F., Yano, M., Ando, T., et al. (2013) Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am. J. Hum. Genet., 93, 173-180.
16. Chen, P.C., Yin, J., Yu, H.W., Yuan, T., Fernandez, M., Yung, C.K., Trinh, Q.M., Peltekova, V.D., Reid, J.G., Tworog-Dube, E., et al. (2014) Next-generation sequencing identifies rare variants associated with Noonan syndrome. Proc. Natl. Acad. Sci. U. S. A., 111, 11473-11478.
17. Cawthon, R.M., Weiss, R., Xu, G.F., Viskochil, D., Culver, M., Stevens, J., Robertson, M., Dunn, D., Gesteland, R., O'Connell, P., et al. (1990) A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell, 62, 193-201.
18. Wallace, M.R., Marchuk, D.A., Andersen, L.B., Letcher, R., Odeh, H.M., Saulino, A.M., Fountain, J.W., Brereton, A., Nicholson, J., Mitchell, A.L., et al. (1990) Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science, 249, 181-186.
19. Viskochil, D., Buchberg, A.M., Xu, G., Cawthon, R.M., Stevens, J., Wolff, R.K., Culver, M., Carey, J.C., Copeland, N.G., Jenkins, N.A., et al. (1990) Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell, 62, 187-192.
20. Eerola, I., Boon, L.M., Mulliken, J.B., Burrows, P.E., Dompmartin, A., Watanabe, S., Vanwijck, R. and Vikkula, M. (2003) Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am. J. Hum. Genet., 73, 1240-1249.
21. Arafeh, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahloun, A., Wilmott, J.S., Gartner, J.J., Di Pizio, A., Winograd-Katz, S., et al. (2015) Recurrent inactivating RASA2 mutations in melanoma. Nature Genetics, 47, 1408-1410.
22. Jeyabalan, N. and Clement, J.P. (2016) SYNGAP1: Mind the Gap. Front. Cell. Neurosci., 10, 32.
23. Hamdan, F.F., Gauthier, J., Spiegelman, D., Noreau, A., Yang, Y., Pellerin, S., Dobrzeniecka, S., Cote, M., Perreau-Linck, E., Carmant, L., et al. (2009) Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation. N. Engl. J. Med., 360, 599-605.
24. Hamdan, F.F., Daoud, H., Piton, A., Gauthier, J., Dobrzeniecka, S., Krebs, M.O., Joober, R., Lacaille, J.C., Nadeau, A., Milunsky, J.M., et al. (2011) De novo SYNGAP1 mutations in nonsyndromic intellectual disability and autism. Biol. Psychiatr., 69, 898-901.
25. Roberts, A.E., Araki, T., Swanson, K.D., Montgomery, K.T., Schiripo, T.A., Joshi, V.A., Li, L., Yassin, Y., Tamburino, A.M., Neel, B.G., et al. (2007) Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat. Genet., 39, 70-74.
26. Tartaglia, M., Pennacchio, L.A., Zhao, C., Yadav, K.K., Fodale, V., Sarkozy, A., Pandit, B., Oishi, K., Martinelli, S., Schackwitz, W., et al. (2007) Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat. Genet., 39, 75-79.
27. Wang, D.Z., Hammond, V.E., Abud, H.E., Bertoncello, I., McAvoy, J.W. and Bowtell, D.D. (1997) Mutation in Sos1 dominantly enhances a weak allele of the EGFR, demonstrating a requirement for Sos1 in EGFR signaling and development. Genes Dev., 11, 309-320.
28. Esteban, L.M., Fernandez-Medarde, A., Lopez, E., Yienger, K., Guerrero, C., Ward, J.M., Tessarollo, L. and Santos, E. (2000) Ras-guanine nucleotide exchange factor sos2 is dispensable for mouse growth and development. Mol. Cell. Biol., 20, 6410-6413.
29. Yamamoto, G.L., Aguena, M., Gos, M., Hung, C., Pilch, J., Fahiminiya, S., Abramowicz, A., Cristian, I., Buscarilli, M., Naslavsky, M.S., et al. (2015) Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome. J. Med. Genet., 52, 413-421.
30. Cordeddu, V., Yin, J.C., Gunnarsson, C., Virtanen, C., Drunat, S., Lepri, F., De Luca, A., Rossi, C., Ciolfi, A., Pugh, T.J., et al. (2015) Activating Mutations Affecting the Dbl Homology Domain of SOS2 Cause Noonan Syndrome. Hum. Mutat., 36, 1080-1087.
31. Rodriguez-Viciana, P., Oses-Prieto, J., Burlingame, A., Fried, M. and McCormick, F. (2006) A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol. Cell, 22, 217-230.
32. Cordeddu, V., Di Schiavi, E., Pennacchio, L.A., Ma'ayan, A., Sarkozy, A., Fodale, V., Cecchetti, S., Cardinale, A., Martin, J., Schackwitz, W., et al. (2009) Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonanlike syndrome with loose anagen hair. Nat. Genet., 41, 1022-1026.
33. Dikic, I. and Schmidt, M.H. (2007) Malfunctions within the Cbl interactome uncouple receptor tyrosine kinases from destructive transport. Eur. J. Cell Biol., 86, 505-512.
34. Niemeyer, C.M., Kang, M.W., Shin, D.H., Furlan, I., Erlacher, M., Bunin, N.J., Bunda, S., Finklestein, J.Z., Sakamoto, K.M., Gorr, T.A., et al. (2010) Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat. Genet., 42, 794-800.
35. Martinelli, S., De Luca, A., Stellacci, E., Rossi, C., Checquolo, S., Lepri, F., Caputo, V., Silvano, M., Buscherini, F., Consoli, F., et al. (2010) Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am. J. Hum. Genet., 87, 250-257.
36. Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M.J. and Shoelson, S.E. (1998) Crystal structure of the tyrosine phosphatase SHP-2. Cell, 92, 441-450.
37. Tartaglia, M., Mehler, E.L., Goldberg, R., Zampino, G., Brunner, H.G., Kremer, H., van der Burgt, I., Crosby, A.H., Ion, A., Jeffery, S., et al. (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet., 29, 465-468.
38. Keilhack, H., David, F.S., McGregor, M., Cantley, L.C. and Neel, B.G. (2005) Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J. Biol. Chem., 280, 30984-30993.
39. Tartaglia, M., Martinelli, S., Stella, L., Bocchinfuso, G., Flex, E., Cordeddu, V., Zampino, G., Burgt, I., Palleschi, A., Petrucci, T.C., et al. (2006) Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am. J. Hum. Genet., 78, 279-290.
40. Digilio, M.C., Conti, E., Sarkozy, A., Mingarelli, R., Dottorini, T., Marino, B., Pizzuti, A. and Dallapiccola, B. (2002) Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am. J. Hum. Genet., 71, 389-394.
41. Legius, E., Schrander-Stumpel, C., Schollen, E., Pulles-Heintzberger, C., Gewillig, M. and Fryns, J.P. (2002) PTPN11 mutations in LEOPARD syndrome. J. Med. Genet., 39, 571-574.
42. Rodriguez-Viciana, P., Tetsu, O., Tidyman, W.E., Estep, A.L., Conger, B.A., Cruz, M.S., McCormick, F. and Rauen, K.A. (2006) Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science, 311, 1287-1290.
43. Pandit, B., Sarkozy, A., Pennacchio, L.A., Carta, C., Oishi, K., Martinelli, S., Pogna, E.A., Schackwitz, W., Ustaszewska, A., Landstrom, A., et al. (2007) Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat. Genet., 39, 1007-1012.
44. Razzaque, M.A., Nishizawa, T., Komoike, Y., Yagi, H., Furutani, M., Amo, R., Kamisago, M., Momma, K., Katayama, H., Nakagawa, M., et al. (2007) Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat. Genet., 39, 1013-1017.
45. Estep, A.L., Palmer, C., McCormick, F. and Rauen, K.A. (2007) Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PloS One, 2, e1279.
46. Wu, J., Harrison, J.K., Dent, P., Lynch, K.R., Weber, M.J. and Sturgill, T.W. (1993) Identification and characterization of a new mammalian mitogen-activated protein kinase kinase, MKK2. Mol. Cell. Biol., 13, 4539-4548.
47. Brott, B.K., Alessandrini, A., Largaespada, D.A., Copeland, N.G., Jenkins, N.A., Crews, C.M. and Erikson, R.L. (1993) MEK2 is a kinase related to MEK1 and is differentially expressed in murine tissues. Cell Growth Differ, 4, 921-929.
48. Alessandrini, A., Brott, B.K. and Erikson, R.L. (1997) Differential expression of MEK1 and MEK2 during mouse development. Cell Growth Differ, 8, 505-511.
49. Anastasaki, C., Estep, A.L., Marais, R., Rauen, K.A. and Patton, E.E. (2009) Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum. Mol. Genet., 18, 2543-2554.
50. Wakioka, T., Sasaki, A., Kato, R., Shouda, T., Matsumoto, A., Miyoshi, K., Tsuneoka, M., Komiya, S., Baron, R. and Yoshimura, A. (2001) Spred is a Sprouty-related suppressor of Ras signalling. Nature, 412, 647-651.
51. Stowe, I.B., Mercado, E.L., Stowe, T.R., Bell, E.L., Oses-Prieto, J.A., Hernandez, H., Burlingame, A.L. and McCormick, F. (2012) A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev., 26, 1421-1426.
52. Brems, H., Chmara, M., Sahbatou, M., Denayer, E., Taniguchi, K., Kato, R., Somers, R., Messiaen, L., De Schepper, S., Fryns, J.P., et al. (2007) Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat. Genet., 39, 1120-1126.
53. Kraft, M., Cirstea, I.C., Voss, A.K., Thomas, T., Goehring, I., Sheikh, B.N., Gordon, L., Scott, H., Smyth, G.K., Ahmadian, M.R., et al. (2011) Disruption of the histone acetyltransferase MYST4 leads to a Noonan syndrome-like phenotype and hyperactivated MAPK signaling in humans and mice. J. Clin. Investig., 121, 3479-3491.
54. Nacak, T.G., Leptien, K., Fellner, D., Augustin, H.G. and Kroll, J. (2006) The BTB-kelch protein LZTR-1 is a novel Golgi protein that is degraded upon induction of apoptosis. J. Biol. Chem., 281, 5065-5071.
55. Piotrowski, A., Xie, J., Liu, Y.F., Poplawski, A.B., Gomes, A.R., Madanecki, P., Fu, C., Crowley, M.R., Crossman, D.K., Armstrong, L., et al. (2014) Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat. Genet., 46, 182-187.
56. Galliano, M.F., Toulza, E., Gallinaro, H., Jonca, N., Ishida-Yamamoto, A., Serre, G. and Guerrin, M. (2006) A novel protease inhibitor of the alpha2-macroglobulin family expressed in the human epidermis. J. Biol. Chem., 281, 5780-5789.
57. Vissers, L.E., Bonetti, M., Paardekooper Overman, J., Nillesen, W.M., Frints, S.G., de Ligt, J., Zampino, G., Justino, A., Machado, J.C., Schepens, M., et al. (2015) Heterozygous germline mutations in A2ML1 are associated with a disorder clinically related to Noonan syndrome. Eur. J. Hum. Genet., 23, 317-324.
58. van Trier, D.C., van Nierop, J., Draaisma, J.M., van der Burgt, I., Kunst, H., Croonen, E.A. and Admiraal, R.J. (2015) External ear anomalies and hearing impairment in Noonan Syndrome. Int. J. Pediatr. Otorhinolaryngol, 79, 874-878.
59. Barnes, H., Larsen, B., Tyers, M. and van Der Geer, P. (2001) Tyrosine-phosphorylated low density lipoprotein receptorrelated protein 1 (Lrp1) associates with the adaptor protein SHC in SRC-transformed cells. J. Biol. Chem., 276, 19119-19125.
60. Craig, J., Mikhailenko, I., Noyes, N., Migliorini, M. and Strickland, D.K. (2013) The LDL receptor-related protein 1 (LRP1) regulates the PDGF signaling pathway by binding the protein phosphatase SHP-2 and modulating SHP-2-mediated PDGF signaling events. PloS One, 8, e70432.
61. Stephen, A.G., Esposito, D., Bagni, R.K. and McCormick, F. (2014) Dragging ras back in the ring. Cancer Cell, 25, 272-281.